Why aren’t health insurers rushing to cover GLP-1 prescriptions for beneficial weight loss?
Dave Pearson|July 22, 2026|Health Exec|Economics
In theory, GLP-1 receptor agonist drugs like semaglutide and tirzepatide should save a lot of money for the health insurers that pay for them.
How? By keeping users thinner and thus healthier over the long haul. Major tests and interventions get avoided. Big claims fall off
Plus, given the proven effectiveness and blockbuster popularity of these drugs—brand names Ozempic, Wegovy, Mounjaro, Zepbound and the like—the savings should scale for payers at population levels.
As it turns out, the lived reality is not keeping pace with the idealistic expectation.
That’s because real-world studies have shown patients often take themselves off the drugs, regaining lost weight and negating long-term health dividends for themselves and their insurers.
Nor does it help that the drugs are still pricey thanks to their high demand, patent protections and complex manufacturing
To make fuller coverage make fiscal sense, payers have to combine a willingness to pay with patients’ faithful participation in lifestyle programs and other measures—and with providers’ partnership in supporting such active supplementation.
‘Tremendous value’—up to a point
All of this comes out in an open-access study published this spring in the Journal of Managed Care & Specialty Pharmacy and an effectiveness-and-value report from the Institute for Clinical and Economic Review (ICER) last December
This week, the lead author of the journal study updates the latest thinking on GLP-1 access and affordability in an informational item posted by his institution, the University of Mississippi
“The ICER report shows that GLP-1s, at the cost that they are currently being sold, provide tremendous value to society,” says the Ole Miss researcher, Sujith Ramachandran, PhD. “But the impact they create on the budget is still massive.”
Just because these drugs deliver favorable outcomes at a decent value, he adds, doesn’t mean “we, as a society, can take the impact of how many individuals [are eligible and] would use this.”
Payers looking hard at prescriptions
Meanwhile Ramachandran’s colleague Liang-Yuan Lin, an Ole Miss doctoral candidate in pharmacy administration, takes up the emerging issue of unapproved GLP-1 drugs finding a market
Noting that the FDA recently issued a warning on these “compounded” drugs, Lin stresses that their sellers cannot be trusted.
“Even if they’re listing the right ingredients, you don’t know where these ingredients are from or how they’ve been transported or handled, which could be really dangerous,” Lin says.
As for FDA-approved GLP-1 receptor agonists, Ramachandran reports that insurers are paying for the drugs to treat certain diagnoses—sleep apnea, diabetes, extremely high BMI or a combination of these things
However, for less-specific indications, “coverage is probably going to get more restrictive.”
Dave Pearson
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations
